Zofia Piotrowska, MD, MHS

Articles

TROP2 and Dato-DXd in EGFRm Non–Small Cell Lung Cancer: Evolving Biomarkers and Treatment Strategies

July 9th 2025

Panelists discuss how TROP2-targeted ADC dato-DXd represents another promising option with evolving digital pathology biomarker approaches, though practical implementation and patient selection strategies remain challenging.

Exploring the Potential Role of HER3-DXd in Advanced EGFRm Non–Small Cell Lung Cancer

July 9th 2025

Panelists discuss how HER3-directed ADC patritumab deruxtecan shows promise as a later-line therapy with approximately 30% response rates and intracranial activity, though biomarker selection remains elusive and mechanism of CNS penetration unclear.

Treatment Selection and Sequencing Strategies for Advanced EGFRm NSCLC in the Second-Line Setting

July 2nd 2025

Panelists discuss how second-line treatment selection depends heavily on frontline therapy choice, emphasizing the importance of repeat biopsies to identify resistance mechanisms and considering continuation of TKI with added chemotherapy for patients with controlled CNS disease.

Balancing Safety and Efficacy in the Frontline Management of Advanced EGFRm NSCLC

July 2nd 2025

Panelists discuss how balancing safety and efficacy in frontline regimens involves managing distinct toxicity profiles, with FLAURA2 requiring standard chemotherapy monitoring vs MARIPOSA necessitating complex supportive care for EGFR-related skin toxicity and venous thromboembolism prophylaxis.

Treatment Strategies for EGFRm Non–Small Cell Lung Cancer With Visceral or Oligometastatic Disease

June 25th 2025

Panelists discuss how oligometastatic disease treatment requires careful definition of metastatic burden, with liver metastases potentially indicating more aggressive biology and warranting consideration of intensified frontline therapy.

Optimizing Treatment in EGFRm NSCLC With CNS Metastases: Multidisciplinary Management and Monitoring Strategies

June 25th 2025

Panelists discuss how CNS metastases in EGFR-mutated NSCLC require multidisciplinary management with close radiation oncology collaboration, frequent monitoring, and preference for FLAURA2 regimen due to superior intracranial efficacy data.

MARIPOSA in First-Line EGFRm Non–Small Cell Lung Cancer: Patient Selection and Emerging Survival Data

June 18th 2025

Panelists discuss how the MARIPOSA regimen (amivantamab plus lazertinib) shows promising overall survival benefits in first-line treatment, though with increased toxicity concerns including rash, edema, and VTE risk requiring careful patient selection.

FLAURA2 in the Frontline Management of EGFRm NSCLC: Key Considerations for Patient Selection

June 18th 2025

Panelists discuss how FLAURA2 regimen (osimertinib plus chemotherapy) is being incorporated into frontline EGFR-mutated NSCLC treatment, with considerations for escalating to combination therapy based on disease burden, CNS metastases, and patient tolerance factors.

Key Takeaways for Concurrent Biomarker Testing in NSCLC

June 18th 2024

Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, emphasize the critical role of both tissue and liquid biopsies, the necessity of rapid time-to-treatment initiation, and the increasing likelihood of liquid biopsies becoming the standard of care for metastatic non-small cell lung cancer patients in the near future.

Overcoming Barriers to NSCLC Biomarker Testing

June 11th 2024

Key opinion leaders delve into the challenges posed by payers, costs, out-of-pocket maximums, and the need for letters of medical necessity, while also addressing additional sources of resistance encountered in clinical practice.

Challenges of NSCLC Biomarker Testing in Clinical Practice

June 11th 2024

Zofia Piotrowska, MD, MHS, shares insights into the challenges and advantages of diagnostic testing practices at Massachusetts General Hospital, including the benefits of on-site testing, the need for less streamlined consent forms, and areas for improvement to expedite the diagnostic testing ordering process.

Reflex Testing for Patients with Suspected Lung Cancer

June 4th 2024

Key opinion leaders highlight findings from a University of Pennsylvania study demonstrating that implementing reflex next-generation sequencing testing can reduce time-to-treatment from 19 days to 10 days, potentially leading to improved overall patient outcomes and survival rates in non-small cell lung cancer.

Biomarker Testing in Early-Stage NSCLC

June 4th 2024

Medical experts recommend that EGFR, ALK, and PD-L1 testing be performed as reflex tests for patients with early-stage non-small cell lung cancer to inform personalized treatment strategies.

Improving Time-to-Treatment for Patients With Non-Small Cell Lung Cancer

May 28th 2024

The expert panel underscores the critical importance of rapid diagnostic testing and identification of driver alterations to optimize patient outcomes, given the often-narrow therapeutic window for chemotherapy and targeted therapies.

NCCN Guidelines: Optimizing NSCLC Treatment with Concurrent Biomarker Testing

May 28th 2024

Key opinion leaders examine the current National Comprehensive Cancer Network (NCCN) guidelines regarding the utilization of liquid and tissue biopsies, highlighting the necessity for the NCCN to prioritize and recommend concurrent testing as the preferred approach over relying on a single liquid or tissue biopsy alone.

Concurrent NSCLC Biomarker Testing at Diagnosis

May 21st 2024

Martin Dietrich, MD, PhD, shares his approach to optimizing the use of diagnostic testing from both a tissue perspective and cost perspective, noting he routinely orders tissue and liquid biopsies during the initial patient visit if prior testing has not been conducted.

Optimizing NSCLC Patient Outcomes Through Concurrent Biomarker Testing

May 21st 2024

Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, emphasize the crucial role of molecular testing in disease diagnosis, focusing on the significance of rapid turnaround times and the ability of liquid biopsies to address time-sensitive diagnostic needs.

Role of Neoadjuvant Therapy in Resectable NSCLC

July 31st 2023

Insights on the use of neoadjuvant therapy in resectable NSCLC, particularly focusing on the use of neoadjuvant IO in EGFR mutated patients and the results of relevant trials.

Selecting Appropriate Adjuvant Therapy for Patients with EGFR-Mutant NSCLC

July 31st 2023

On the subject of patient eligibility, the panel deliberates on the decision-making process between osimertinib and chemotherapy and outlines adjuvant therapy options.

Routine Molecular Testing in Early NSCLC Post-Resection

July 24th 2023

Recommendations for community oncologists concerning molecular testing, including the types of tests, timing best practices, and how the results should inform treatment decisions.